Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YAA OPPONG

Allopathic & Osteopathic Physicians Hospitalist

NPI
1487898748
CMS profile
405491
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$120.65

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $120.65 7

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YAA OPPONG

NPI 1487898748 · CMS profile ID 405491

Allopathic & Osteopathic Physicians / Hospitalist

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487898748?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YAA OPPONG, NPI 1487898748, CMS profile ID 405491. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487898748?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). YAA OPPONG, NPI 1487898748, CMS profile ID 405491. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487898748?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
YAA OPPONG, NPI 1487898748, CMS profile ID 405491, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1487898748?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $120.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mylan Specialty L.P. $17.1806/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751391319 CMS
Mallinckrodt Hospital Products Inc. $13.1406/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751714109 CMS
GlaxoSmithKline, LLC. $18.6703/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738802053 CMS
GlaxoSmithKline, LLC. $18.4603/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738539457 CMS
Relypsa, Inc. $19.6602/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742184735 CMS
Otsuka America Pharmaceutical, Inc. $16.2002/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748768215 CMS
GlaxoSmithKline, LLC. $17.3402/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738538147 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $393.80 19
PY2020 $120.65 7
PY2021 $68.91 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $51,483.92 5
PY2022 Principal investigator $4,815,557.18 223
PY2021 Principal investigator $1,929,253.72 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

63 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $15,213.07 12/31/2021 Non-covered Recipient Entity
CAROLINA INSTITUTE FOR CLINICAL RESEARCH, LLC
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 848739013
Principal investigator 1 Janssen Research & Development, LLC $182,242.00 12/28/2021 Non-covered Recipient Entity
Carolina Inst For Clnc Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787637415
Principal investigator 1 ModernaTX, Inc. $875.95 12/27/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944457
Principal investigator 1 ModernaTX, Inc. $10,298.48 12/27/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944461
Principal investigator 1 ModernaTX, Inc. $20,418.75 12/27/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944465
Principal investigator 1 ModernaTX, Inc. $21,309.75 12/27/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944467
Principal investigator 1 ModernaTX, Inc. $39,548.25 12/27/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944477
Principal investigator 1 ModernaTX, Inc. $40,058.55 12/27/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944479
Principal investigator 1 ModernaTX, Inc. $1,000.00 12/27/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research - M3 WR - ERN - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 860944489
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/27/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research - M3 WR - ERN - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 860944491
Principal investigator 1 PFIZER INC. $12,000.00 12/24/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research LLC
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 832555413
Principal investigator 1 ModernaTX, Inc. $282.15 11/19/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944455
Principal investigator 1 ModernaTX, Inc. $22,126.50 11/19/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944469
Principal investigator 1 ModernaTX, Inc. $26,278.43 11/19/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944471
Principal investigator 1 ModernaTX, Inc. $26,278.43 11/19/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944473
Principal investigator 1 ModernaTX, Inc. $39,548.25 11/17/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944475
Principal investigator 1 ModernaTX, Inc. $14,579.46 10/27/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944463
Principal investigator 1 ModernaTX, Inc. $44,624.25 10/27/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944483
Principal investigator 1 ModernaTX, Inc. $5,255.69 10/22/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944459
Principal investigator 1 ModernaTX, Inc. $44,102.61 10/22/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944481
Principal investigator 1 ModernaTX, Inc. $63,944.17 10/22/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944485
Principal investigator 1 ModernaTX, Inc. $89,958.60 10/13/2021 Non-covered Recipient Entity
Carolina Institute for Clinical Research, LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860944487
Principal investigator 1 Moderna TX, Inc. $46,586.81 09/29/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334103
Principal investigator 1 Moderna TX, Inc. $1,308.96 09/29/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334137
Principal investigator 1 Moderna TX, Inc. $4,091.18 09/29/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334161
Principal investigator 1 Moderna TX, Inc. $148.50 09/29/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334217
Principal investigator 1 Moderna TX, Inc. $46,783.04 09/29/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334299
Principal investigator 1 Moderna TX, Inc. $6,792.86 09/29/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334339
Principal investigator 1 Moderna TX, Inc. $2,054.50 09/29/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334438
Principal investigator 1 Moderna TX, Inc. $289.58 09/29/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334531
Principal investigator 1 Moderna TX, Inc. $42,391.35 09/15/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334525
Principal investigator 1 Moderna TX, Inc. $22,126.50 09/01/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334283
Principal investigator 1 Moderna TX, Inc. $28,215.00 08/11/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334097
Principal investigator 1 Moderna TX, Inc. $423.23 08/11/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334107
Principal investigator 1 Moderna TX, Inc. $22,720.50 08/11/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334241
Principal investigator 1 Moderna TX, Inc. $1,070.89 08/11/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334287
Principal investigator 1 Moderna TX, Inc. $8,182.35 08/11/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334307
Principal investigator 1 Moderna TX, Inc. $6,726.71 08/11/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334379
Principal investigator 1 Moderna TX, Inc. $205.20 08/11/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334415
Principal investigator 1 Moderna TX, Inc. $564.30 08/11/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334487
Principal investigator 1 Moderna TX, Inc. $41,334.30 08/04/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334469
Principal investigator 1 Moderna TX, Inc. $1,625.40 07/28/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334113
Principal investigator 1 Moderna TX, Inc. $7,149.60 07/28/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334119
Principal investigator 1 Moderna TX, Inc. $30,753.00 07/28/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334129
Principal investigator 1 Moderna TX, Inc. $15,267.15 07/28/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334133
Principal investigator 1 Moderna TX, Inc. $1,625.40 07/28/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334151
Principal investigator 1 Moderna TX, Inc. $7,214.40 07/28/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334223
Principal investigator 1 Moderna TX, Inc. $4,158.00 07/28/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334247
Principal investigator 1 Moderna TX, Inc. $15,707.25 07/28/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334349
Principal investigator 1 Moderna TX, Inc. $34,919.10 07/28/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334353
Principal investigator 1 Moderna TX, Inc. $6,211.35 07/28/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334451
Principal investigator 1 Moderna TX, Inc. $3,793.50 07/28/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334455
Principal investigator 1 Moderna TX, Inc. $21,455.25 07/23/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334175
Principal investigator 1 Moderna TX, Inc. $22,943.25 07/14/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334253
Principal investigator 1 Moderna TX, Inc. $41,698.80 07/14/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334427
Principal investigator 1 Moderna TX, Inc. $156,204.45 07/01/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334141
Principal investigator 1 Moderna TX, Inc. $182,079.90 07/01/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334201
Principal investigator 1 Moderna TX, Inc. $188,963.57 07/01/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334303
Principal investigator 1 Moderna TX, Inc. $55,215.00 07/01/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334333
Principal investigator 1 Moderna TX, Inc. $3,985.20 07/01/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334443
Principal investigator 1 Moderna TX, Inc. $7,411.50 07/01/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334466
Principal investigator 1 Moderna TX, Inc. $71,559.45 07/01/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334543
Principal investigator 1 Moderna TX, Inc. $45,854.10 06/18/2021 Non-covered Recipient Entity
CAROLINA INS FOR CLIN RESEARCH LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 806334123